BRIEF—STA Pharma facility passes EU inspection

A new Shanghai-based facility owned by WuXi AppTec subsidiary STA Pharmaceutical has passed its first GMP inspection by the European Medical Products Agency (MPA).

The site was opened at the end of 2018, after WuXi STA merged with WuXi AppTec's Pharmaceutical Development Services unit. Another new commercial drug product facility was built in Wuxi City to support the new entity’s operations.

WuXi STA has received US FDA inspections at both its API manufacturing facility in Shanghai and its API R&D & manufacturing facility in Changzhou.